Our
Approach

THROUGH THE PFENEX EXPRESSION TECHNOLOGY WE ARE ABLE TO EFFICIENTLY AND EFFECTIVELY DEVELOP LOWER COST, HIGHER QUALITY VACCINES.

Capitalizing on our long history of rapidly identifying production strains for antigens that cannot be readily produced in other systems, we are able to develop and produce vaccines faster, in larger quantities and of a higher quality than other pharmaceutical developers. This positions us as an important biodefense player and, as such, we are a vital partner to the U.S. government in the development of a next generation anthrax vaccine candidate.

This vaccine, an anthrax recombinant Protective Antigen (rPA) vaccine – Px563L – is fully-funded by the U.S. government to potentially provide top-quality products to the Strategic National Stockpile, helping to potentially fulfill the government’s unmet demand for increased quantity, stability, and dose sparing regimens of anthrax vaccine and ensure the future safety of all Americans and our allies against any manmade or environmental biological threats.